Devonian Bolsters Intellectual Property With Issuance of U.S. Patent Covering a Method of Treatment of Inflammatory Bowel Disease

QUÉBEC, Québec -- Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued patent no. 11,723,938 B2 entitled, “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease” covering a method for treating inflammatory bowel disease (“IBD”) such as ulcerative colitis and Crohn’s disease in a human subject with an effective amount of active thylakoid extract. Read More